Paradigm Genetics has wrapped up its acquisition of privately held TissueInformatics in an all-stock deal worth more than $4 million.

TissueInformatics is based in Pittsburgh, PA.

Paradigm said the combined company now has 212 employees. The TissueInformatics unit will remain in Pittsburgh.

TissueInformatics develops and applies automated pathology software for analysis of tissue changes that occur during drug discovery, disease assessment, toxicology and tissue engineering.

Paradigm issued 3.4 million shares with a value of $4.5 million to TissueInformatics shareholders. Another 2.7 million shares will be issued later this year on what the company called an “earn-out” basis.

Peter Johnson, M.D., the chairman and chief executive officer of TissueInformatics, and Mark Braughler, senior vice president of business development, will join Paradigm’s management team. Johnson becomes executive vice president and chief medical officer. Braughler will be vice president of business development for healthcare.